FDA Approves Otezla for Psoriatic Arthritis Treatment

The U.S. Food and Drug Administration has approved Otezla (apremilast) for the treatment of psoriatic arthritis in adults.

Advertisement

Manufactured by Summit, N.J.-based Celgene Corp., Otezla demonstrated improvements in symptoms of psoriatic arthritis, such as tender and swollen joints and physical function, in clinical trials.

More Articles on FDA Approvals:

FDA Approves Xolair for Chronic Hives
FDA Approves Neuraceq for Brain Imaging
FDA Approves Implantable Device for Certain Type of Hearing Loss

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.